Cardiology
Partner With Us
Advertisement
Conexiant chevron_right Cardiology chevron_right Weight Loss Drugs Heavier Implications
From the Journals Clinical Guidelines

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant
Full Article Summary Notecard
  1. NuSH therapies are recommended for weight loss and reducing CVD risk.
  2. Over 40% of U.S. adults have obesity.
  3. Weight loss >15% correlates with lower cardiovascular mortality.
  4. Liraglutide, Semaglutide, and Tirzepatide are key agents.
  5. Approximately 4%-7% may discontinue therapy due to side effects.
  6. Obesity management requires a multidisciplinary approach.
  7. High costs and limited reimbursement hinder access to treatments.

Source: JACC

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.